[go: up one dir, main page]

AR128110A1 - Tetrahidropirazolopirimidinas y análogos relacionados para la inhibición de yap / taz tead - Google Patents

Tetrahidropirazolopirimidinas y análogos relacionados para la inhibición de yap / taz tead

Info

Publication number
AR128110A1
AR128110A1 ARP220103591A ARP220103591A AR128110A1 AR 128110 A1 AR128110 A1 AR 128110A1 AR P220103591 A ARP220103591 A AR P220103591A AR P220103591 A ARP220103591 A AR P220103591A AR 128110 A1 AR128110 A1 AR 128110A1
Authority
AR
Argentina
Prior art keywords
tead
yap
taz
tetrahydropyrazolopyrimidines
inhibition
Prior art date
Application number
ARP220103591A
Other languages
English (en)
Inventor
Bart Vanderhoydonck
Arnaud Marchand
Ii Stephen L Gwaltney
Wim Smets
Aurlie Candi
Matthias Versele
Amuri Kilonda
Original Assignee
The Katholieke Univ Leuven
Springworks Therapeutics Inc
Vib Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Katholieke Univ Leuven, Springworks Therapeutics Inc, Vib Vzw filed Critical The Katholieke Univ Leuven
Publication of AR128110A1 publication Critical patent/AR128110A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se refiere a compuestos novedosos, a dichos compuestos para su uso como un fármaco, más particularmente para la prevención o el tratamiento de enfermedades mediadas por la actividad de la transcripción de YAP / TAZ-TEAD, aún más particularmente para la prevención o el tratamiento del cáncer o la fibrosis. La presente descripción también se refiere a un método para la prevención o el tratamiento de dichas enfermedades que comprende el uso de los compuestos novedosos.
ARP220103591A 2021-12-23 2022-12-26 Tetrahidropirazolopirimidinas y análogos relacionados para la inhibición de yap / taz tead AR128110A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163293538P 2021-12-23 2021-12-23

Publications (1)

Publication Number Publication Date
AR128110A1 true AR128110A1 (es) 2024-03-27

Family

ID=86903815

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103591A AR128110A1 (es) 2021-12-23 2022-12-26 Tetrahidropirazolopirimidinas y análogos relacionados para la inhibición de yap / taz tead

Country Status (14)

Country Link
US (1) US20230279016A1 (es)
EP (1) EP4452254A4 (es)
JP (1) JP2025501773A (es)
KR (1) KR20240137563A (es)
CN (1) CN118613257A (es)
AR (1) AR128110A1 (es)
AU (1) AU2022419653A1 (es)
CL (1) CL2024001894A1 (es)
CO (1) CO2024009582A2 (es)
IL (1) IL313630A (es)
MX (1) MX2024007929A (es)
PE (1) PE20250833A1 (es)
TW (1) TW202333679A (es)
WO (1) WO2023122783A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119968359A (zh) 2022-09-29 2025-05-09 英矽智能科技知识产权有限公司 Tead抑制剂及其使用方法
WO2025019604A2 (en) * 2023-07-18 2025-01-23 The General Hospital Corporation Proteolysis targeting chimeras for treating neurodegeneration
WO2025088534A1 (en) * 2023-10-27 2025-05-01 Dong-A St Co., Ltd. Bicyclic heterocycle compounds as tead inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3313838T (lt) * 2015-06-29 2019-06-10 Astrazeneca Ab Policikliniai amido dariniai, kaip cdk9 slopikliai
CN112204029B (zh) * 2018-05-31 2024-03-01 豪夫迈·罗氏有限公司 治疗性化合物
IL301691A (en) * 2020-09-30 2023-05-01 Univ Leuven Kath 1,2,3,4-tetrahydroquinoline derivatives as inhibitors of the yap/taz-tead activation for treating cancer

Also Published As

Publication number Publication date
EP4452254A2 (en) 2024-10-30
CO2024009582A2 (es) 2024-10-21
PE20250833A1 (es) 2025-03-21
US20230279016A1 (en) 2023-09-07
MX2024007929A (es) 2024-09-10
CL2024001894A1 (es) 2024-12-06
AU2022419653A1 (en) 2024-07-18
JP2025501773A (ja) 2025-01-23
CN118613257A (zh) 2024-09-06
EP4452254A4 (en) 2025-12-31
WO2023122783A2 (en) 2023-06-29
KR20240137563A (ko) 2024-09-20
WO2023122783A3 (en) 2023-08-24
TW202333679A (zh) 2023-09-01
IL313630A (en) 2024-08-01
WO2023122783A8 (en) 2024-07-25

Similar Documents

Publication Publication Date Title
AR128107A1 (es) Anilinas de 2-pirazol y análogos relacionados para inhibir yap / taz-tead
AR128108A1 (es) Indoles, indazoles y análogos relacionados para inhibir yap / taz-tead
AR128110A1 (es) Tetrahidropirazolopirimidinas y análogos relacionados para la inhibición de yap / taz tead
MX2022007515A (es) Inhibidores de sos1.
CO2023005342A2 (es) Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead para el tratamiento del cancer
ECSP22087539A (es) Inhibidores de kras tricíclicos fusionados
CO2024001285A2 (es) Compuestos tricíclicos como inhibidores de kras
MX2025000271A (es) Inhibidores de kras de anillo fusionado para el tratamiento de enfermedades
DOP2018000222A (es) Inhibidores de mcl1 macrocíclicos para tratar el cáncer antecedentes
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
MX2022001697A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
MX2020007060A (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
CO2020012169A2 (es) Compuestos de aminopirazina diol como inhibidores de pi3k-y
ECSP22044525A (es) Terapia de combinaci?n que comprende un inhibidor de alk2 y un inhibidor de jak2
AR128109A1 (es) Spiros y análogos relacionados para inhibir yap / taz-tead
CL2021001656A1 (es) Compuestos de imidazopiridina e imidazopiridina y sus usos.
CO2024017767A2 (es) Sales de inhibidores de sos1
MX2022013081A (es) Compuestos para el tratamiento de sars.
MX2020004678A (es) Uso de profarmacos de riluzol para tratar ataxias.
CO2025016647A2 (es) Inhibidores de egfr para el tratamiento de enfermedades
MX2024007937A (es) Tetrahidrobenzoazepinonas y analogos relacionados para la inhibicion de yap/taz-tead.
UY39779A (es) Compuestos macrocíclicos para tratar enfermedades
CO2022017969A2 (es) Compuestos de imidazopiridazina con actividad como inhibidores de alk2
MX2022001023A (es) Compuestos de aminotiolester y usos de los mismos.
DOP2025000274A (es) Inhibidores de egfr para el tratamiento de enfermedades